


## Romania

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous survey: ▲ Improvement ▼ Decline		2009		2012		2015		2018
International units	Factor VIII	0.72	<b>A</b>	1.10	•	1.06	<b>A</b>	2.29
per capita	Factor IX	0.24	•	0.11	•	0.11	<b>A</b>	0.27
Organisation	Comprehensive Care Centres (CCC's)	Yes		Yes		Yes		Yes
of care	Haemophilia Treatment Centres	Yes		Yes		Yes		Yes
	National Haemophilia Council or Co-ordinating Group	Yes	•	No	<b>A</b>	Yes		Yes
	Number of groups in decision-making on haemophilia care	2	▼	1	<b>A</b>	3	•	2
	Number of groups choosing haemophilia treatment products	1		1		1	<b>A</b>	2
	National Tender for procurement of factor concentrates	No		No		No		No
Treatment	Home Treatment	No		No	<b>A</b>	Yes		Yes
regimens	% of people with haemophilia using home treatment	<10%		<10%	<b>A</b>	10-50%		10-50%
	Treatment delivered to the patient's home	No		No		No		No
	Prophylaxis treatment availability	Some		Some		Some		Some
	Children currently on prophy (%)	1-25%		0		51-75%	<b>A</b>	76-100%
	Adults currently on prophy (%)	0		0		0		1-25%
	Access to ITI (% of people with inhibitors)	0		0		0		0
Access to	Emergency medicine and acute surgery	Yes		Yes		Yes		Yes
specialist services	Paediatrics	Yes		Yes		Yes		Yes
	Infectious disease specialists (especially HIV)	Yes		Yes		Yes		Yes
	Hepatology	Yes		Yes		Yes		Yes
	Rheumatology	Yes		Yes		Yes		Yes
	Orthopaedics	Yes		Yes		Yes		Yes
	Physiotherapy	Yes		Yes	•	Sometimes	<b>A</b>	Yes
	Dentistry	Yes		Yes	•	Sometimes	<b>A</b>	Yes
	Obstetrics and Gynaecology	Yes		Yes	•	Sometimes	<b>A</b>	Yes
	Genetics	Yes	•	Sometimes		Sometimes		Sometimes
	Social and psychological support	Yes	•	Sometimes		Sometimes	<b>A</b>	Yes
	Pain management	Yes		Yes	•	Sometimes	<b>A</b>	Yes
	General surgery	Yes	•	Sometimes	<b>A</b>	Yes		Yes
	Urology	Yes		Yes		Yes		Yes
Share of Expected	Haemophilia A	66%	<b>A</b>	70%	<b>A</b>	73%	<b>A</b>	83%
Bleeding Disorder	Haemophilia B	31%	<b>A</b>	32%	<b>A</b>	33%	<b>A</b>	36%
Prevalence	von Willebrand Disease	2%	<b>A</b>	2%	•	1%	<b>A</b>	2%
Haemophilia	Pasma-derived factor concentrate	Rarely	<b>A</b>	Always		Always		Always
replacement	Recombinant factor concentrate	Rarely	<b>A</b>	Always	•	Rarely	<b>A</b>	Always
therapy	Plasma	Always	<b>A</b>	Never	•	Rarely	<b>A</b>	Never
	Cryoprecipitate	Rarely	<b>A</b>	Never	▼	Rarely	<b>A</b>	Never
VWD replacement	Plasma-derived factor concentrate	Rarely	<b>A</b>	Always		Always		Always
therapy	DDAVP	Rarely		Rarely		Rarely		Rarely
	Plasma	Rarely		Rarely		Rarely	_	Never